

BIBLIOGRAPHY
“HANDBOOK FOR EBV TESTING AND TREATMENT
IN SEVERE, CHRONIC PAIN CONDITIONS”

1. Aalto SM, Linnavuori K, Peltola, et al. Immunocostivation of Epstein-Barr virus due to cytomegalovirus disease. *J Med Virol* 1998;56:186-91. Andre G, Trompet E, Snoeck R. Novel therapeutics for Epstein-Barr virus. *Molecules* 2019;24:997-1009.
2. Anderson D, Fanberge I, Hedstrom AK. Treatment options for Epstein-Barr virus related disorders of the central nervous system. *Infect and Drug Resist* 2023;16:4599-4620.
3. Bilello J, Tennant F. Patterns of chronic inflammation in extensively treated patients with arachnoiditis and chronic intractable pain. *Postgrad Med* 2016;92:1-5.
4. Binne UK, Amun W, Furrell PJ. Promotor sequence required for reactivation of Epstein-Barr virus from latency. *J Virology* 2002;76:10282-10289.
5. Bjornevik K, Cortese M, Healy BC, et al, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science* 2022;375:296-301.
6. Chang DM, Chu SJ, Chen HC, et al. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. *Ann Rheum Dis* 2004;63:1623-1620.
7. Cohen JL. Epstein-Barr Virus infection. *New Eng J Med* 2000;343:481-492.
8. Coskum O, Sener K, Kilic S, et al. Stress-related Epstein-Barr virus reactivation. *Clin Exp Med* 2010;10:15-20.
9. Duan Y, et al. Immune cell infiltration and the genes associated with ligamentum flavum hypertrophy: identification and validation. *Front Cell Dev Biol* 2022;10:91478.
10. Epstein MA, Barr YM, Achang BC. Virus particles in cultured lymphocytes from Burkitt's lymphoma. *Lancet* 1964;1:702-703.
11. Harley JB, Chan X, Pujato M, et a. Transaction factors operate across disease loci, with EBNA2 implicated in autoimmunity. *Nat Genet* 2018;50:699-707.
12. Harrow T. Epstein-Barr virus could be a cause of multiple autoimmune disorders. *VA Research Currents* April 18, 2018.
13. Henle G, Henle N, Diehl V. Relation of Burkitt's tumor associated herpes type virus to infectious mononucleosis. *Proc Natl Acad Sci* 1968;59:94-101.
14. Henle G, Henle W, Klein G, et al. Antibodies to early Epstein-Barr virus-induced antigens in Burkitt's lymphoma. *J Nat Cancer Inst* 1971;46:861-871.
15. Henle W, Henle G. Epstein-Barr virus-related serology in Hodgkin's disease. *Nat Cancer Inst Monograph* 1973;36:79-84.
16. Houen G, Trier NH. Epstein-Barr virus and systemic autoimmune disease. *Front Immunol* 2020;11:1-13.
17. Hsu D, Malefytro W, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF 1. *Science* 1990;250:830-832.
18. Indari O, Tiwari D, Tanwar M, et al. Early biomolecular changes in brain microvascular endothelial cells under Epstein-Barr virus influence: A Raman microspectroscopic investigation. *Integr Biol* 2022;14:89-97.
19. Indari O, Jakhomola S, Pathak DK, et al. Comparative account of biomolecular changes post Epstein Barr virus infection of the neuronal and glial cells using Raman microspectroscopy. *ACS Chem Neurosci* 2022;13:1627-1637.

20. Jakhmola S, Jha HM. Glial cell response to Epstein Barr Virus infection: a plausible contribution to virus-associated inflammatory reactions in the brain. *Virology* 2021;559:182-195.
21. Jha HC, Pei Y, Robertson ES. Epstein-Barr virus: disease linked to infection and transformation. *Front Microbiol* 2016;7:1-16.
22. Jones KJ. Gonadal steroids and neuronal regeneration: a therapeutic role. *Adv Neurol* 1993;59:227-240.
23. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. *Semin Cancer Biol* 2014;26:60-68.
24. Kerr J. Epstein Barr Virus (EBV) reactivation and therapeutic inhibitors. *J Clin Pathol* 2019;0:1-8.
25. Kiefer R, Kreutzberg GW. Effects of dexamethasone on microglial activation in vitro. *J Neuroimmunology* 1991;34:99-108.
26. Kingsbury SR, Tharmanathan P, KKeding A, et al. Pain reduction with oral methotrexate in knee osteoarthritis. *Ann Intern Med* 2024;177:1145-1156.
27. Klanner FR. The treatment of poliomyelitis and other virus diseases with vitamin C. *So Med Surg* 1949;111:209-214.
28. Kumar K, Polston GR, Wallace MS. The effect of intravenous ketorolac on capsaicin-induced deep tissue hyperalgesia. *Anesth Analg* 2006;103:696-702.
29. Li YL, Wang JY, Lil K, et al. Epstein-Barr virus to be a trigger of autoimmune glial fibrillary acidic protein astrocytopathy. *CNS Neurosci Ther* 2023;29:4139-4146.
30. Libert N, Bigailon C, Chargari C, et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. *Biomed J* 2015;38:70-76.
31. Nagata K, Hayashi K. Epstein-Barr virus reactivation-induced immunoglobulin production: significance on autoimmunity. *Microorganisms* 2020;8:1875-1890.
32. Nakamura M, Burasteros F, Vaki Y, et al. Proving the normal and autoimmune B cell repertoire with Epstein-Barr virus, frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. *J Immunol* 1998;141:4165-4172.
33. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr infection. *Am J Hematol* 2005;80:64-69.
34. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. *Prog Brain Res* 2010;186:13-137.
35. Rhodes G, Pumpold H, Kurki P, et al. Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen. *J Exp Med* 1987;165:1026-1040.
36. Rickinson AB. Chronic symptomatic Epstein-Barr virus infection. *Immunol Today* 1986;7:13-14.
37. Romundstad L, Breivik A, Niemi G, et al. Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. *Acta Anaesthesiol Scand* 2004;48:1223-1231.
38. Sausen DG, Bhutto MS, Gallo ES, et al. Stress-induced Epstein-Barr virus reactivation. *Biomolecules* 2021;11:1380-1410.
39. Soni N, Ora R, Sing P, et al. Unpacking the CNS manifestations of Epstein-Barr virus: an imaging perspective. *Amer J Neurorad* 2023;44:1002-1008.

40. Sotgin ML, Riella G, Formaglio F, et al. Central effort of ketorolac involving NMDA receptors activity. *Brain Res* 1998;223-226
41. Strauss SE. The chronic mononucleosis syndrome. *J Infect Dis* 1988;157:405-412.
42. Stubhaug A, Romundstad L, Kaasa T, et al. Methylprednisolone and ketorolac rapidly reduce hyperalgesia around a skin burn injury and increase pressure pain thresholds. *Acta Anaesth Scand* 2007;51:1138-1146.
43. Sumaya CV, Henle W, Henle G, et al. Seroepidemiologic study of Epstein-Barr virus infections in a rural community. *J Infect Disease* 1975;131:403-408.
44. Sumaya, CV. Endogenous reactivation of Epstein-Barr virus infection. *J Infect Dis* 1977;135:374-379.
45. Sunderson B, Shirafkan F, Ripperger K, et al. The role of viral infections in the onset of autoimmune diseases. *Viruses* 2023;15:782-814.
46. Sutton RN, Emond RT, Thomas DB, et al. The occurrence of autoantibodies in infectious mononucleosis. *Clin Exp Immunol* 1974;17:427-436.
47. Takahashi H, Sugura T, Okazimo Y, et al. Inflammatory cytokines in the herniated disc of the lumbar spine. *Spine* 1996;21:218-224.
48. Takedo K, Sawamura S, Sekiyama H, et al. Effect of methylprednisolone on neuropathic pain and spinal glial activation in rats. *Anesthesiology* 2004;100:1249-1257.
49. Teitelbaum J. Effective treatment for chronic fatigue syndrome and fibromyalgia: an overview and 35 treatments for tough cases. *Townsend Letter* Nov, 2015:56-59.
50. Tennant F. The physiologic effects of pain on the endocrine system. *Pain Ther* 2013;2:75-86.
51. Tiwari D, Mittal N. Unraveling the links between neurodegeneration and Epstein-Barr virus-mediated cell cycle dysregulation. *Curr Res Neurobiol* 2023;3:2665-2945.
52. Vaughn JH. The Epstein-Barr virus in autoimmunity. *Springer Semin Immunopathol* 1995;17:203-230.
53. Werner MY, Lassen B, Kehlet H. Analgesic effects of dexamethasone in burn injury. *Reg Anesth Pain Med* 2002;27:254-260.
54. Zang Y, Chee A, Shi P, et al. Intervertebral disc cells produce interleukins found in patients with back pain. *Am J Phys Med* 2016;95:407-415.
55. Zhang N, Zou Y, Jiang L, et al. Epstein Barr virus and neurologic diseases. *Front Mol Biosci* 2022;10:1-34.